NanoVibronix, Inc. (NASDAQ: NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse ...

Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today ...

ContractHeidelberg Pharma Amends Royalty Financing with HealthCare Royalty 13-March-2025 / 00:31 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, ...

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, ...

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced ...

During World War 1, Abbott's antiseptic agent, chlorazene ... Firstly, the TDx therapeutic drug montiroing system was introduced, followed by the US approval of a new epilepsy treatment, Depakote ...

There was no evidence of clinically significant central adverse events, whereas drowsiness, dry mouth and nausea were reported with comparator agents (levodropropizine, codeine, DL-cloperastine).

HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with ...

With hundreds of free agents set to hit the open market, things will continue to heat up. NFL free agency begins this week, with the legal tampering period opening things up on March 10 at noon ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD ...

Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...